efpia disclosure & consent management
TRANSCRIPT
![Page 1: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/1.jpg)
EFPIA Disclosure and Consent Management
![Page 2: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/2.jpg)
Speakers
Ned MumtazPractice Leader Life Science, qordata
Brian P. SharkeyJD; Vice President, Porzio Life Sciences, LLC (TBC)
Elisabeth KohoutecAssociate, King & Spalding (TBC)
Moderator
![Page 3: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/3.jpg)
![Page 4: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/4.jpg)
![Page 5: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/5.jpg)
Takeaway From This Webinar:
Attendees of the webinar will acquire detailed insight into issues related to transparency and consent management in Europe. The topics in the webinar include:
•Practical experiences with implementing a transparency solutions.•The biggest legal risks in managing transparency.•Impact of transparency on stake holders.
Related topics that would be covered:
•Upcoming changes in consent management regulation•Expectations of consent rates in the next round of disclosures
![Page 6: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/6.jpg)
Expert Panel discussion on EFPIA Transparencyand Physician Consent Management
![Page 7: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/7.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
• In your opinion what worked well for the manufacturers in reporting spend transparency information in 2015 and 2016 and where do you see opportunities for improvement?
• Collecting Spend Information• Receiving Physician Consent• Engaging Physicians• Producing Transparency Reports• Adopting Policies and Procedure• Others
![Page 8: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/8.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
• I would like to next discuss your opinion on the impact of EFPIA Transparency on:
• Manufacturer’s business practices, physician relationship with manufacturers, Industrial Associations and Public at large.
• We will cover each in turn.
![Page 9: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/9.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
• Manufacturer’s business practices: • Has the spend reporting and consent collection process affected
pharmaceutical manufacturers business policies and practices in your opinion?
![Page 10: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/10.jpg)
Physicians or Physician Organizations: • Have the physicians or physician
associations or organizations responded to the reporting of spend or collection of consent. Do you have an opinion on the drivers for the range of variation in consent approval. For example according to EFPIA varied from nearly 95% in Latvia, 65% in Italy and 20% in Spain?
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
![Page 11: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/11.jpg)
EFPIA believes that interactions between the pharmaceutical industry and healthcare professionals have a profound and positive influence on the quality of patient treatment and the value of future research. At the same time, the integrity of the decision of a healthcare professional to prescribe a medicine is one of the pillars of the healthcare system.
• Industry Associations: • Did EFPIA succeed in meeting its transparency goals in 2015 and
2016? What about the member organizations?
![Page 12: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/12.jpg)
Other Stakeholders: • What has been the reaction of patients, patient organizations,
public at large, and legislature?
The General Data Protection Regulation (GDPR) (Regulation (EU) 2016/679) is a regulation by which the European Parliament, the European Council and the European Commission intend to strengthen and unify data protection for individuals within the European Union (EU).
Barcelona, May 26th 2016. Farmaindustria reinforces its commitment with transparency by approving the individual disclosure of transfers of value to healthcare professionals
![Page 13: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/13.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
What recommendations could you share for the manufacturers to improve their consent collection process?
• Most manufacturers have not provided for consent revocation. Is there a risk?
• Many manufacturers have managed the process on paper. Is there a risk of loosing the paper documents or failing to retain them?
![Page 14: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/14.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
Resources being endless – what in your judgment might be the best practice to manage consent, consent record keeping, consent revocation and consent sharing with physicians?
![Page 15: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/15.jpg)
Expert Panel discussion on EFPIA Transparency and Physician Consent Management
If time permits:Kindly share any general thoughts or opinions you have as learnings from your roles as a business practitioner and legal practitioner supporting the manufacturers in pharmaceutical industry.
![Page 16: EFPIA Disclosure & Consent Management](https://reader036.vdocument.in/reader036/viewer/2022062523/58edcf011a28ab8b538b459f/html5/thumbnails/16.jpg)
Thank You